← Back to Search

Beta-3 Adrenergic Agonist

Mirabegron for Temperature Regulation

Q: Does this experiment open its doors to those of advanced age?

This research project is seeking individuals between the legal age of consent and 40 years old.

Q: Do I meet the criteria to join this investigation?

The candidate selection criteria for this trial stipulates that those who wish to participate should have thermoregulatory control and be between the ages of 18-40. 15 people are needed in total.

Q: Is this research protocol currently open for enrollment?

Correct. Per the information published on clinicaltrials.gov, this research initiative is actively enlisting patients. It was first posted on April 27th 2023 and has been updated as recently as August 21st of the same year. The study requires 15 volunteers from a single site to take part in it.

Q: How many participants are engaged in this research experiment?

Affirmative. According to the information provided on clinicaltrials.gov, this research endeavour is actively recruiting participants, with 15 people needed from 1 site. The study was initially posted on April 27th 2023 and then updated most recently on August 21st 2023.

Phase < 1

Waitlist Available

Led By Christopher Bell, Ph.D.

Research Sponsored by Christopher Bell

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Age 18-40 years

Be between 18 and 65 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up immediately after each infusion.

Awards & highlights

Study Summary

This trial found that taking mirabegron can increase fat-burning and improve glucose regulation, possibly changing muscle structure.

Who is the study for?

This trial is for healthy adults aged 18-40 who exercise regularly (over 150 minutes of moderate intensity weekly) for the past two years. It's not suitable for pregnant or breastfeeding individuals, those with heart, lung, metabolic diseases like diabetes, liver/kidney problems, or on certain medications that don't mix well with Mirabegron.Check my eligibility

What is being tested?

The study tests if Myrbetriq (Mirabegron), a drug normally used to treat overactive bladder, can increase body heat produced by brown fat compared to a placebo. The goal is also to see if it has long-term benefits on glucose regulation and muscle changes.See study design

What are the potential side effects?

Possible side effects of Mirabegron include increased blood pressure, urinary tract infections, headaches, dizziness, nausea and could potentially interact unfavorably with other drugs.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am between 18 and 40 years old.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ immediately after each infusion.

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~immediately after each infusion.

This trial's timeline: 3 weeks for screening, Varies for treatment, and immediately after each infusion. for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Change in core temperature measured via oral thermometer during each stage.

Change in metabolic rate compared to baseline during each stage as measured by indirect calorimetry

Change in temperature among the top 10% of hottest pixels as identified via thermal camera and FLIR research software in the supraclavicular region during each isoproterenol infusion.

Side effects data

From 2019 Phase 4 trial • 28 Patients • NCT02086188

urinary tract infection

asthma

gastritis

fatigue

diarrhea

headache

100%

80%

60%

40%

20%

Study treatment Arm

Placebo

Mirabegron

Trial Design

2Treatment groups

Experimental Treatment

Placebo Group

Group I: Mirabegron + IsoproterenolExperimental Treatment1 Intervention

100mg oral + Isoproterenol IV Infusion; 3 doses, 6, 12, 24ng/ kg Fat Free Mass

Group II: Placebo + IsoproterenolPlacebo Group1 Intervention

Empty Capsule + Isoproterenol IV Infusion; 3 doses, 6, 12, 24ng/ kg Fat Free Mass

0 / 1Eligibility criteria met

Find a Location

Who is running the clinical trial?

Indiana UniversityOTHER

980 Previous Clinical Trials

983,142 Total Patients Enrolled

Christopher BellLead Sponsor

7 Previous Clinical Trials

179 Total Patients Enrolled

Christopher Bell, Ph.D.Principal InvestigatorColorado State University

1 Previous Clinical Trials

62 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Does this experiment open its doors to those of advanced age?

"This research project is seeking individuals between the legal age of consent and 40 years old."

Answered by AI

Do I meet the criteria to join this investigation?

"The candidate selection criteria for this trial stipulates that those who wish to participate should have thermoregulatory control and be between the ages of 18-40. 15 people are needed in total."

Answered by AI

Is this research protocol currently open for enrollment?

"Correct. Per the information published on clinicaltrials.gov, this research initiative is actively enlisting patients. It was first posted on April 27th 2023 and has been updated as recently as August 21st of the same year. The study requires 15 volunteers from a single site to take part in it."

Answered by AI

How many participants are engaged in this research experiment?

"Affirmative. According to the information provided on clinicaltrials.gov, this research endeavour is actively recruiting participants, with 15 people needed from 1 site. The study was initially posted on April 27th 2023 and then updated most recently on August 21st 2023."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Does Mirabegron Increase the Body Heat Generated by the Nervous System

Christopher Bell 2023. "Does Mirabegron Increase the Body Heat Generated by the Nervous System". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT06011265.